<DOC>
	<DOC>NCT00073047</DOC>
	<brief_summary>The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. Participants in the study will have a number of visits to a research center over a five-month period. All study related care and medication is provided to qualified participants at no cost: this includes all visits, examinations, and laboratory work.</brief_summary>
	<brief_title>Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<criteria>Moderate to severe active ulcerative colitis diagnosed for at least 4 months. Mayo score of 510 (inclusive) Not used any investigational therapy for 30 days prior to screening No treatment with monoclonal antibody therapy within 12 weeks of screening No prior treatment with daclizumab</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Humanized Monoclonal antibody</keyword>
</DOC>